Oral vs Intravenous Diltiazem for Rapid Atrial Fibrillation/Flutter Trial

• Status: Recruiting
• Trial end date: 2023-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this study is to compare the incidence of rate control (defined as:

HR <110 beats/min or conversion to sinus rhythm) at 2 hours after medication administration between oral immediate release diltiazem and intravenous continuous infusion diltiazem.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Virginia Commonwealth University
• Treatments: Diltiazem

Criteria

Inclusion Criteria:

• >/= 18 years old

• Atrial fibrillation or flutter on electrocardiogram

• Heart rate >110 beats/min

• Systolic blood pressure >/= 90 mmHg

Exclusion Criteria:

• Limited English proficiency (LEP)

• Pregnant

• Prisoners

• Wolff Parkinson White syndrome

• Administration of electrical or chemical cardioversion before screening

• Administration of other antiarrhythmics for acute heart rate control (excluding adenosine)

• History of allergy or idiosyncratic reaction to diltiazem

• Unable to take oral medications

• Heart rate <60 beats/min